Form D · Pharmaceuticals
BioAnalytix LLC
Boston, MA · CIK 0001556289
Offering snapshot reported Aug 16, 2012 · SEC filing
- Reported sold
- $858K Offering amount: $858K
- Investors reported
- 11 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 31, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 16, 2012 | Initial | $857,587 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-182814
Source: Form D, filed Aug 16, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Robert Garnick | Director, Executive |
| Kirtland G Poss | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
110 Mugar Building 330 Huntington Avenue
Boston, MA, 02115
Boston, MA, 02115